Thomas-Jardin Shayna, Suresh Shruthy, Arce Ariana, Novaresi Nicole, Deng Qing, Stein Emily, Thomas Lisa, Lewis Cheryl, Ahn Chul, Evers Bret M, Akbay Esra A, Salvatierra Maria E, Lu Wei, Khan Khaja, Solis Soto Luisa M, Wistuba Ignacio I, Minna John D, O'Donnell Kathryn A
Department of Molecular Biology, UT Southwestern Medical Center, Dallas, Texas.
CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.
Cancer Res. 2025 Jul 15;85(14):2574-2590. doi: 10.1158/0008-5472.CAN-24-3844.
The integrated stress response (ISR) is an adaptive pathway hijacked by cancer cells to survive cellular stresses in the tumor microenvironment. ISR activation potently induces PD-L1, leading to suppression of antitumor immunity. In this study, we sought to uncover additional immune checkpoint proteins regulated by the ISR to elucidate mechanisms of tumor immune escape. The ISR coordinately induced cluster of differentiation 155 (CD155) and PD-L1, enhancing translation of both immune checkpoint proteins through bypass of inhibitory upstream open reading frames in their 5' untranslated regions. Analysis of primary human lung tumors identified a significant correlation between expression of PD-L1 and CD155. ISR activation accelerated tumorigenesis and inhibited T-cell function, which could be overcome by combining PD-1 and TIGIT blockade with the ISR inhibitor ISRIB. This study uncovers a mechanism by which two immune checkpoint proteins are coordinately regulated and suggests a therapeutic strategy for patients with lung cancer.
The integrated stress response represents a targetable axis to improve the efficacy of immunotherapy in lung cancer by inhibiting the coordinated translational regulation of the PD-L1/PD-1 and CD155/TIGIT immune checkpoint pathways.
整合应激反应(ISR)是癌细胞劫持的一条适应性途径,用于在肿瘤微环境中应对细胞应激并存活。ISR激活会强力诱导程序性死亡配体1(PD-L1),导致抗肿瘤免疫受到抑制。在本研究中,我们试图揭示受ISR调控的其他免疫检查点蛋白,以阐明肿瘤免疫逃逸机制。ISR协同诱导分化簇155(CD155)和PD-L1,通过绕过其5'非翻译区中的抑制性上游开放阅读框来增强这两种免疫检查点蛋白的翻译。对原发性人肺肿瘤的分析确定了PD-L1和CD155表达之间存在显著相关性。ISR激活加速肿瘤发生并抑制T细胞功能,联合使用程序性死亡受体1(PD-1)和T细胞免疫球蛋白和ITIM结构域(TIGIT)阻断剂与ISR抑制剂ISRIB可克服这一问题。本研究揭示了一种协调调控两种免疫检查点蛋白的机制,并为肺癌患者提出了一种治疗策略。
整合应激反应代表了一个可靶向的轴,通过抑制PD-L1/PD-1和CD155/TIGIT免疫检查点途径的协同翻译调控来提高肺癌免疫治疗的疗效。